|View printer-friendly version|
|Quidel to Hold Third Quarter 2010 Results Conference Call on October 27, 2010|
SAN DIEGO, Oct 13, 2010 (BUSINESS WIRE) --
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, will release third quarter 2010 financial results after market close on Wednesday, October 27, 2010.
Following the release of results, Douglas Bryant, president and chief executive officer, and John M. Radak, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss those results and to answer questions.
To participate in the live call by telephone from the U.S., dial 866-804-6928, or from outside the U.S. dial 857-350-1674, and enter the pass code 57002201.
A live webcast of the call can be accessed at http://www.quidel.com, and the website replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on October 27 by dialing 888-286-8010 from the U.S., or 617-801-6888 for international callers, and entering pass code 82884944.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the leading brand names QuickVue(R), D3(R) Direct Detection and Thyretain(TM), Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
SOURCE: Quidel Corporation